Trial Profile

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 101 Artiva Biotherapeutics (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
Indications Granulomatosis with polyangiitis; Pemphigus vulgaris; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions
Acronyms IRIS-RD-01

Most Recent Events

12 Nov 2024 According to an Artiva Biotherapeutics media release, initial data for AlloNK in autoimmune indications from this Phase 1/1b trial or the investigator-initiated basket trial (IIT) expected in the first half of 2025.
04 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com